Log in

NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

$17.47
+0.01 (+0.06 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$17.38
Now: $17.47
$17.83
50-Day Range
$15.47
MA: $17.25
$18.50
52-Week Range
$9.50
Now: $17.47
$20.84
Volume50,808 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CLLS
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees161
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.


Cellectis (NASDAQ:CLLS) Frequently Asked Questions

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.18. The biotechnology company earned $2.93 million during the quarter, compared to analyst estimates of $3.45 million. View Cellectis' Earnings History.

When is Cellectis' next earnings date?

Cellectis is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Cellectis.

What price target have analysts set for CLLS?

6 Wall Street analysts have issued 12-month target prices for Cellectis' shares. Their forecasts range from $20.00 to $73.00. On average, they expect Cellectis' stock price to reach $40.40 in the next twelve months. This suggests a possible upside of 131.3% from the stock's current price. View Analyst Price Targets for Cellectis.

What is the consensus analysts' recommendation for Cellectis?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.

Has Cellectis been receiving favorable news coverage?

News coverage about CLLS stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cellectis earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Cellectis.

Are investors shorting Cellectis?

Cellectis saw a drop in short interest in January. As of January 31st, there was short interest totalling 226,800 shares, a drop of 7.5% from the January 15th total of 245,100 shares. Based on an average daily trading volume, of 134,600 shares, the short-interest ratio is currently 1.7 days. Approximately 0.5% of the company's stock are short sold. View Cellectis' Current Options Chain.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Exelixis (EXEL), Editas Medicine (EDIT), Micron Technology (MU), Alibaba Group (BABA), WEC Energy Group (WEC) and Neurocrine Biosciences (NBIX).

Who are Cellectis' key executives?

Cellectis' management team includes the folowing people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
  • Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
  • Mr. Eric Dutang, Chief Financial Officer (Age 45)
  • Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
  • Mr. Jean Charles Epinat, Chief Technological Officer

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Cellectis' major shareholders?

Cellectis' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (7.50%), ARK Investment Management LLC (3.16%), Nikko Asset Management Americas Inc. (3.01%), Sumitomo Mitsui Trust Holdings Inc. (3.01%), Credit Suisse AG (1.09%) and Rhenman & Partners Asset Management AB (0.34%).

Which institutional investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., UBS Group AG, Cubist Systematic Strategies LLC, Victory Capital Management Inc. and Eqis Capital Management Inc..

Which institutional investors are buying Cellectis stock?

CLLS stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, ARK Investment Management LLC, Capital Asset Advisory Services LLC, Atria Investments LLC, OneAscent Financial Services LLC, Granite Point Capital Management L.P., Envestnet Asset Management Inc. and Vident Investment Advisory LLC.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $17.47.


MarketBeat Community Rating for Cellectis (NASDAQ CLLS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel